Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children

Author:

Domachowske Joseph1,Hamrén Ulrika Wählby2,Banu Irfana3,Baronio Roberta4,Basavaraju Bhanu3,Koen Anthonet5,Leach Amanda6,Mankad Vaishali S.7,Pannaraj Pia S.8,Soler-Palacin Pere9,Takas Therese6,Mori Masaaki10,Villafana Tonya6,

Affiliation:

1. aState University of New York Upstate Medical University Syracuse, New York

2. bClinical Pharmacology and Quantitative Pharmacology, R&D, AstraZeneca, Gothenburg, Sweden

3. cClinical Development, Vaccines and Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

4. dBiometrics, Vaccines and Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

5. eSouth African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit (Wits-VIDA), Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

6. fClinical Development, Vaccines and Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland

7. gClinical Development, Vaccines and Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Durham, North Carolina

8. hUniversity of California San Diego, San Diego, California

9. iPediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d’Hebron, and Vall d’Hebron Research Institute, Barcelona, Catalonia, Spain

10. jDepartment of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Abstract

BACKGROUND AND OBJECTIVES: Immunocompromised children may have increased risk for severe respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI), potentially leading to prolonged hospitalization, intensive care, and death. The open-label phase II MUSIC trial evaluated the safety and pharmacokinetics of nirsevimab, an extended half-life monoclonal antibody against RSV, in immunocompromised children aged ≤24 months. METHODS: Participants received a single intramuscular injection of nirsevimab (first RSV season: 50 mg if <5 kg/100 mg if ≥5 kg; second season: 200 mg). Safety, antidrug antibodies, and pharmacokinetics were evaluated to day 361. RESULTS: Participants (n = 100) had ≥1 immunocompromising conditions: primary immunodeficiency (n = 33), previous transplantation (n = 16), HIV infection (n = 8) or treatment with high-dose systemic corticosteroids (n = 29), immunosuppressive chemotherapy (n = 20), or other immunosuppressive therapies (n = 15). Six children experienced eight treatment-related adverse events (none categorized as serious). Three deaths occurred, all were unrelated to treatment. Eleven children, developed antidrug antibodies, with minimal effects on pharmacokinetics and no apparent impact on safety. Nirsevimab serum concentrations at day 151 were similar to those effective in preventing medically attended RSV LRTI in healthy infants. Fourteen children had increased nirsevimab clearance. No protocol-defined medically attended RSV LRTIs occured through day 151. CONCLUSIONS: Among immunocompromised children aged ≤24 months, nirsevimab was well tolerated with no safety concerns and serum concentrations were supportive of efficacy. A subset of children with increased nirsevimab clearance, had conditions potentially associated with protein loss; however, the impact on efficacy is unknown.

Publisher

American Academy of Pediatrics (AAP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3